ASH 2024 Myeloma QOL | Abstract Finder

Abstract Number: 774 – The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Presenter: Salomon Manier, MD, PhDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple MyelomaDate & Time: Monday, December 9, 2024 11:45 AM–12:00 PMLocation: Pacific Ballroom Salons 21-22 (Marriott Marquis...

Abstract Number: 706 – Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma

Presenter: Jay R. Hydren, PhDSession: 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting OutcomesDate & Time: Sunday, December 8, 2024 5:15 PM–5:30 PMLocation: San Diego Ballroom AB (Marriott Marquis San Diego...

Abstract Number: 705 – Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Presenter: Jens Hillengass, MD, PhDSession: 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting OutcomesDate & Time: Sunday, December 8, 2024 5:00 PM–5:15 PMLocation: San Diego Ballroom AB (Marriott Marquis San Diego...

Abstract Number: 671 – A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Presenter: Urvi A. Shah, MDSession: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in MyelomaDate & Time: Sunday, December 8, 2024 5:30 PM–5:45 PMLocation: Pacific Ballroom Salons 24-26 (Marriott Marquis...

Abstract Number: 385 – Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial

Presenter: Bryony Dawkins, MScSession: 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow – Improving Safety of TreatmentsDate & Time: Saturday, December 7, 2024 4:00 PM–4:15 PMLocation: Room 6B (San Diego...

Abstract Number: 285 – Lovesick: Examining Couples Health during Myeloma Transplant

Presenter: Ashley Rosko, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple MyelomaDate & Time: Saturday, December 7, 2024 2:30 PM–2:45 PMLocation: Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego...

« Older Entries

Abstract Number: 774 – The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Abstract Number: 706 – Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma

Abstract Number: 705 – Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Abstract Number: 671 – A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Abstract Number: 385 – Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial

Abstract Number: 285 – Lovesick: Examining Couples Health during Myeloma Transplant

Recent Posts

Recent Comments

Archives

Categories

Meta